{"nctId":"NCT03010631","briefTitle":"Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers","startDateStruct":{"date":"2016-11-16","type":"ACTUAL"},"conditions":["Healthy Volunteers"],"count":49,"armGroups":[{"label":"Cohort 1 (Treatment Sequence AB)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cohort 1: Lubiprostone Capsule, Fasted","Drug: Cohort 1: Lubiprostone Sprinkle Formulation, Fasted"]},{"label":"Cohort 1 (Treatment Sequence BA)","type":"EXPERIMENTAL","interventionNames":["Drug: Cohort 1: Lubiprostone Capsule, Fasted","Drug: Cohort 1: Lubiprostone Sprinkle Formulation, Fasted"]},{"label":"Cohort 2 (Treatment Sequence CD)","type":"EXPERIMENTAL","interventionNames":["Drug: Cohort 2: Lubiprostone Sprinkle Formulation, Fed","Drug: Cohort 2: Lubiprostone Sprinkle Formulation, Fasted"]},{"label":"Cohort 2 (Treatment Sequence DC)","type":"EXPERIMENTAL","interventionNames":["Drug: Cohort 2: Lubiprostone Sprinkle Formulation, Fed","Drug: Cohort 2: Lubiprostone Sprinkle Formulation, Fasted"]}],"interventions":[{"name":"Cohort 1: Lubiprostone Capsule, Fasted","otherNames":["AMITIZAÂ®","Treatment A"]},{"name":"Cohort 1: Lubiprostone Sprinkle Formulation, Fasted","otherNames":["Lubiprostone microbeads","Treatment B"]},{"name":"Cohort 2: Lubiprostone Sprinkle Formulation, Fed","otherNames":["Lubiprostone microbeads","Treatment C"]},{"name":"Cohort 2: Lubiprostone Sprinkle Formulation, Fasted","otherNames":["Lubiprostone microbeads","Treatment D"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is male or female, between 18 and 55 years of age, inclusive.\n* Has a 12-lead electrocardiogram (ECG) within normal limits and is in good health based upon review of medical history, physical examination results, vital signs (within normal range), and normal laboratory profile for both blood and urine.\n\nExclusion Criteria:\n\n* Has an active or recent history of alcoholism or drug addiction (within 1 year prior)\n* Is a smoker or has a recent history of smoking (within 6 months)\n* Routinely consumes food known to alter drug metabolism (i.e., grapefruit juice, coffee, tea, cola, chocolate, cocoa, or other caffeine or methyl-xanthine containing foods or beverages) and/or cannot refrain from these items\n* Has donated blood within 3 months\n* Has a medical/surgical condition that might interfere with the absorption, distribution, metabolism, or excretion of the study medication.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cohort 1: Area Under the Concentration-time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t) of M3 Metabolite","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117.518","spread":"57.56"},{"groupId":"OG001","value":"163.615","spread":"47.45"}]}]}]},{"type":"PRIMARY","title":"Cohort 1: Maximum Observed Concentration (Cmax) of M3 Metabolite","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.463","spread":"55.56"},{"groupId":"OG001","value":"127.729","spread":"61.32"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Total Exposure (AUC0-t) of M3 With Administration of Sprinkle Lubiprostone Under Fed Versus (vs) Fasted Condition","description":null,"paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"135.805","spread":"58.17"},{"groupId":"OG001","value":"152.900","spread":"26.96"}]}]}]},{"type":"SECONDARY","title":"Cohort 2: Maximum Observed Concentration (Cmax) of M3 Metabolite in Fed vs Fasted Conditions","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.192","spread":"30.52"},{"groupId":"OG001","value":"116.815","spread":"31.93"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is any untoward medical occurrence that results in death;is life-threatening;requires inpatient hospitalization or prolongation of present hospitalization;results in persistent or significant disability/incapacity;is a congenital anomaly/birth defect;or is a medically important event that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the participant or may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":["Diarrhoea","Nausea","Abdominal pain","Headache","Dizziness"]}}}